Pharmacogenetics in neuropsychopharmacology: from clinical associations to intermediate phenotypes of drug response
Auch gedruckt in der BibliothekZ: J-H 13.626; W: W-H 12.103
LizenzStandard (Fassung vom 01.10.2008)
The human genome contains a lot of different types of variations, such as polymorphisms, insertions/deletions and different number of copies of certain fragment. Through different mechanisms some of them may influence individual’s therapy response, occurrence of adverse reaction or cause the susceptibility to certain disease. It’s necessary to carry out the studies that reveal the genetic variations helping to predict the treatment outcome or if an individual will develop certain disease; this is the main step to the personalized medicine that is going to bring the profit to both patients and physicians. Sometimes it’s not easy to evaluate the state of patients, especially when dealing with neurological and psychological disorders. The important parameter in between is an intermediate phenotype that is a surrogate biomarker and is a qualitative measure that allows to make more accurate diagnose and assess the disease progress and monitor response to the treatment. During the work on this thesis there were performed three projects, having similar purpose: to test the effect of polymorphisms involved to the pathway of the intermediate phenotype manifestation.
Erstellung / Fertigstellung
Normierte SchlagwörterBiomarker [GND]
Alzheimer's disease [MeSH]
Polymorphism, genetic [MeSH]